Skip to content
OpenCapital
Get started

Boston Scientific BSX Interventional Cardiology & Vascular Therapies — Net Sales

Other product segments

Electrophysiology
$905M+24.0%
Endoscopy
$736M+9.4%
Urology
$646M+2.1%
Cardiac Rhythm Management
$578M0.0%
Watchman
$506M+19.1%
Neuromodulation
$318M+17.3%
Interventional Oncology & Embolization
$214M—

Similar metrics at other companies

Fortive logo
FTVMedical technologies — Sales
$308.1M+12.4%
Viatris logo
VTRSNet sales — Net Sales
$3.85B-5.1%
Medtronic logo
MDTUNITED STATES — Net Sales
$4.87B+7.1%
STERIS logo
STEProduct — Revenue
$845.3M+5.5%
Medtronic logo
MDTOther Operating Segments, Including Diabetes — Net Sales
$811.75M+12.3%
ResMed logo
RMDDevices — Net revenue by segment
$1.47B+8.8%

Other financials

Income statement

See full
Revenue$5.2B+11.6%
Gross profit$3.6B+12.6%
Operating income$1.1B+19.5%
Net income$1.3B+99.3%
EPS (diluted)$0.90+100%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.4%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$67.32B-37.5%
P/E18.9×-34.3×
P/S3.3×-2.9×

Profitability

See full
Gross margin69.2%+0.5pp
Operating margin18.4%+2.2pp
Net margin17.3%+5.7pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Boston Scientific’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's interventional cardiology & vascular therapies — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's interventional cardiology & vascular therapies — net sales?
Boston Scientific (BSX) reported interventional cardiology & vascular therapies — net sales of $1.16B in Q4 2025.
How has Boston Scientific's interventional cardiology & vascular therapies — net sales changed year-over-year?
Boston Scientific's interventional cardiology & vascular therapies — net sales increased by 10.5% year-over-year, from $1.05B to $1.16B.
What is the long-term trend for Boston Scientific's interventional cardiology & vascular therapies — net sales?
Over 2 years (2023 to 2025), Boston Scientific's interventional cardiology & vascular therapies — net sales has grown at a 10.6% compound annual growth rate (CAGR), from $3.79B to $4.64B.
What does interventional cardiology & vascular therapies — net sales mean?
The total revenue earned from selling medical devices used in heart and vascular procedures.
How do you interpret interventional cardiology & vascular therapies — net sales?
An increase indicates growing adoption of the company's cardiovascular technologies and successful market expansion, while a decrease may signal increased competition, pricing pressure, or a slowdown in procedure volumes.
How does interventional cardiology & vascular therapies — net sales compare across companies?
Comparable to cardiovascular segment revenues reported by major medical device peers like Medtronic, Abbott, or Edwards Lifesciences, often analyzed alongside procedure volume trends.